

Cytosorb application in a case of severe Rivaroxaban associated bleeding: a potential life saving therapy.



De Pascalis A, Barbarini S, Ria P, Zito A, Napoli M

UOC Nefrologia, Dialisi e Trapianto, Ospedale Vito Fazzi, Lecce, Italy

Background

Rivaroxaban is an oral X Factor inhibitor that is used to prevent blood clotting. We present a severe bleeding complication due to use of Rivaroxaban and we discuss the indication to early treatment with CytoSorb.

Case Report

A 68-year-old female patient, on anticoagulant therapy because of previous MI, was admitted to the emergency department with hemodynamically hypotensive cardiogenic shock state, with reduced urine output and acute renal failure. The general condition of the patient was poor; therefore, she was intubated, subsequently, after finding of severe anemia (Hb 5.1 g/dL), the patient was transfused until the hemodynamics stabilized. Contrast abdominal computed tomography (CT) was performed which showed large areas of hemorrhage-hematoma were present in the right psoas ileus and right kidney. 48 hours post admission, Rivaroxaban specific antiXa activity resulted still altered and after three successive embolizations, spontaneous bleeding was still present. Treatment with Cytosorb allowed stabilization of the clinical picture, normalization of antiXA activity and patient survival.